ATTN: We are committed to keeping our patients informed regarding the recent cybersecurity incident involving McKesson. At this time, we are continuing to monitor the situation closely and are working to obtain the most current information available. We will provide updates as we receive additional information from McKesson and learn more about any potential impact. Thank you for your patience and trust as we navigate this situation together. CLICK HERE for more information.

Virginia Oncology Associates

Virginia Oncology Associates

Clinical Research & Trials

Cancer Center » Clinical Research & Trials » Available Trials » USO 23335
Patient Portal Cancer Resources

Listen to our podcast

RSS Feed

USO 23335

A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

 

Disease Types: Melanoma Research

Eligibility Requirements:

• Histologically confirmed unresectable stage III and stage IV
(metastatic) melanoma
• Uveal, acral or mucosal melanoma are not eligible
• No prior systemic therapy for unresectable or metastatic
melanoma
• Pt with adjuvant/neoadjuvant therapy without PD during treatment
are eligible if disease-free and treatment-free for over 6 months
• No prior immune checkpoint inhibitor therapy other than anti-PD1/PD-L1
• Measurable disease per RECIST version 1.1
• Previously irradiated lesions can be used as target lesions only if
demonstrated to progress and no other target lesion is available
• Cutaneous lesions are considered non-target lesions
• Patients must have known BRAF V600 status

For more information on this trial CLICK HERE .

Available at:

Virginia Oncology Associates